Overview / Abstract: |
STATEMENT OF NEED Of the estimated 74,680 new cases of non-Hodgkin lymphoma each year in the United States, approximately 35% are follicular lymphoma (FL), an indolent, difficult-to-treat B-cell malignancy. Most patients are diagnosed at an average age of 65 years. Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrences with available therapies are common. Currently, allogeneic hematopoietic stem cell transplant is the only curative therapeutic modality for relapsed/refractory disease. However, the risk for comorbidities and secondary cancers limit the utility of this treatment upfront. Further research is required to determine the optimal timing and role of transplant and novel therapies to keep the remission rate among FL patients high and durable. TARGET AUDIENCE Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with FL. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: Evaluate predictive and prognostic markers that can inform personalized care plans for patients with FL |
Expiration |
Jan 03, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.25 |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Christopher R. Flowers, MD, MS (Chairperson) |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Bayer Healthcare Pharmaceuticals, Inc. and Celgene Corporation. |
Keywords / Search Terms |
i3 Health i3 Health, follicular lymphoma, lymphoma, non-Hodgkin lymphoma, B-cell lymphoma, hematologic malignancies, oncology, CME, CE, webinar, free CE, free CME, CEU, CNE Free CE CME |